retatrutide for obesity Why Is Gaining Attention in Peptide Weight Loss Therapy A New Obesity Drug Delivered

Avoiding novel compounds or unapproved enzymes is essential to manage food safety and regulatory exposure

MathieuCRanettiAELiDEkholmECookWHirshbergBet al

Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Erectile Dysfunction: A Drug Target Mendelian Randomization Study

Early Discoveries, With More to Come So far, GLP-1s, first approved 20 years ago for type 2 diabetes and later obesity, have shown potential in treating a surprisingly wide range of conditions, such as heart disease, Parkinsons, Alzheimers, sleep apnea, and liver disease

Effective obesity treatment that reduces cardiovascular events could substantially decrease this burden while improving quality of life for millions of Canadians